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Abstract
The Syphilis Health Check (SHC) had low estimated specificity (91.5%) in one Florida county. 
We investigated use of SHC by a range of Florida publicly-funded programs between 2015 and 
2016 to estimate specificity, positive predictive value (PPV), field staff acceptance, and impacts on 
programmatic outcomes. All reported SHC results were extracted from routinely collected 
program data. Field staff were surveyed about SHC’s utility. Analyses investigated differences 
between SHC and traditional syphilis testing outcomes. Of 3,630 SHC results reported, 442 were 
reactive; 92 (20.8%) had prior diagnoses of syphilis; 7 (1.6%) had no further testing. Of the 
remaining 343; 158 (46.0%) were confirmed cases, 168 (49.0%) were considered false-positive, 
and 17 (5.0%) were not cases but not clearly false-positive. Estimated specificity of SHC was 
95.0%. Overall, 48.5% of positives became confirmed cases (PPV). PPV varied according to 
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prevalence of syphilis in populations tested. Staff (90%) thought SHC helped identify new cases 
but expressed concern regarding discordance between reactive SHC and lab-based testing. 
Programmatic outcomes assessment showed shorter time to treatment and increased numbers of 
partners tested for the SHC group; these enhanced outcomes may better mitigate the spread of 
syphilis compared to traditional syphilis testing alone, but more research is needed.
BACKGROUND
The U.S. Food and Drug Administration granted the first-ever Clinical Laboratory 
Improvement Amendments waiver for a rapid treponemal syphilis screening test, Syphilis 
Health Check, in December 2014 (FDA, 2014). Accurately identifying new cases of 
syphilis, administering timely treatment, and securing timely partner notification for testing 
and treatment are cornerstones of successful public health interventions to control the spread 
of syphilis.
The SHC may facilitate these interventions, but very few studies have investigated its 
performance in the field. One small cohort study found that sensitivity was 71.4% and 
specificity was 91.5%, significantly lower than the >98% specificity reported for SHC 
(Matthias et al., 2016). Findings from a larger United States cohort study using 2014 – 2016 
data to investigate the performance of SHC showed that sensitivity ranged from 88.7% to 
95.7% and specificity ranged from 93.1% to 93.2%, depending on the method of 
confirmatory test result consensus used (Pereira et al., 2018). Other studies have found 
mixed results with a range of sensitivity (61.1% to 92.0%), specificity (92.7% to 99.6%), 
and positive predictive value (9.4% to 97.5%) (Jafari et al., 2013; Seña, White, & Sparling, 
2010; Toskin et al., 2017).
Few studies have assessed the acceptability of the SHC among healthcare workers and 
patients (Ansbro et al., 2015; Swartzendruber, Steiner, Adler, Kamb, & Newman, 2015), and 
none have been from the United States. A rapid point of care test could reduce clinic waiting 
time, allow same-day treatment, facilitate outreach testing, and allow substitution of finger-
stick for venipuncture (Ansbro et al., 2015; Swartzendruber et al., 2015). Faster 
identification of new syphilis cases could decrease time to treatment and facilitate partner 
treatment.
Purpose
Florida has multiple syphilis testing sites across the state and routinely captures testing and 
case management information, including time to treatment and numbers of partners named, 
tested, infected, and treated. We aimed to describe the results of SHC testing in Florida after 
a state-wide implementation and the impact on programmatic outcomes. Moreover, we 
surveyed the staff that used SHC to identify benefits and challenges to using it in the field.
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METHODS
Data Extraction and Study Population
All records for adults tested with SHC from 08/01/2015 through 12/31/2016 were extracted, 
de-identified, and compiled. The SHC was performed by health department staff who had 
been trained in administering the SHC. Test settings varied based on program needs. Data 
included syphilis testing location, test type, test results, case/non-case determination, 
treatment, and partner services outcomes. We excluded persons who required testing for 
congenital syphilis or neurosyphilis, as the SHC test is not appropriate for determining these 
types of syphilis. This was a program evaluation of standard routine public health practices 
using de-identified programmatic data. Thus, it was determined not to be human subjects 
research.
SHC Reactivity Rate Determination
All 67 Florida health departments were given the opportunity to receive SHC kits for rapid 
syphilis testing free of charge. Each health department self-selected whether to use the SHC 
at its site or not. If a health department did request SHC kits to use, the only stipulation was 
that the health department had to report all SHC test results to the health department of the 
county in which the patient resides. Training of field staff for use of the SHC was provided 
by the SHC distributor. All tests reported in this study were done by health departments. A 
total of 35 Florida counties conducted SHC testing. For inter-county comparison, data was 
stratified by volume of SHC tests given for the top 11 SHC-using counties and combined for 
the small volume remaining in the other 24 counties. The top 11 counties, in order of 
greatest number of SHC tests conducted to the least, were Orange, Miami-Dade, Escambia, 
Lee, Alachua, Polk, Duval, Leon, Hillsborough, Palm Beach, and Brevard.
The performance of the SHC was investigated at both statewide and county levels. Variables 
of interest were SHC test result status (positive or negative), agreement or discordance 
between SHC results and traditional testing (non-treponemal and/or treponemal) results, new 
syphilis cases identified from SHC testing, and new syphilis cases treated as the result of 
positive SHC test results.
We excluded from the analyses any SHC test results that were done on persons with a 
history of past syphilis or when there were no associated confirmatory test results. The 
prevalence of syphilis among persons appropriately tested was estimated as the number of 
new syphilis cases reported divided by the number of persons tested. The Council for State 
and Territorial Epidemiologists (CSTE) case definition for reported syphilis cases was used 
to determine new cases.(Sosa, 2017) Specific to this study, new cases were assessed and 
classified by local program staff. For this evaluation, SHC reactive tests without both a 
reactive treponemal and non-treponemal test or a diagnosis of primary syphilis by a provider 
were considered inconclusive. Positive predictive value (PPV) was calculated after excluding 
persons with inconclusive results on additional testing. Thus, PPV was the new cases 
divided by the sum of the new cases plus the false positives, times 100. Specificity was 
estimated by considering all negative SHC to be true negatives. No false negative SHC were 
identified because persons who tested negative on the SHC were not retested. The specificity 
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is the number of true negatives divided by the sum of the true negatives plus the false 
positives, times 100.
Programmatic Outcomes Assessment Comparing SHC with Traditional Syphilis Testing
In order to identify programmatic benefits of the SHC, we conducted analyses comparing 
cases identified using the SHC administered by health department staff with cases identified 
at public health departments using traditional syphilis testing in the 11 Florida counties that 
did the most SHC testing during the defined study period for 2015 and 2016. Treatment data 
were collected by health department staff from syphilis investigations conducted by 
healthcare providers. Timeliness of treatment was calculated by subtracting the recorded 
date of treatment from the date of specimen collection. The outcome variables were 
timeliness of treatment, number of named partners, number of named partners tested, 
number of named partners infected, and number of infected partners treated (see Variables of 
Interest, Appendix 1).
Survey Interviews of Field Staff
Field staff interviews were conducted from 09/27/2017 through 10/19/2017 using a 27-
question survey instrument to assess the value of the SHC as a screening test and its 
effectiveness as a tool to prevent the spread of syphilis (see Survey Instrument, Appendix 2). 
Survey participants were not chosen at random, rather they were chosen based on expertise 
with the SHC. Participants consisted of one program manager and those field staff who had 
the most experience administering the SHC test as identified by the Florida Department of 
Health STD program. The roles served by these field staff included syphilis testing, 
supervising staff who conduct syphilis testing, and those involved in follow-up partner 
services. Field staff participating in the survey were representative of the top 11 SHC-using 
Florida counties: Orange, Miami-Dade, Escambia, Lee, Alachua, Polk, Duval, Leon, 
Hillsborough, Palm Beach, and Brevard. For consistency, all surveys were conducted by one 
research team member via telephone interview.
Data Analysis
Statistical analyses were done using SAS 9.4 (Cary, NC) and OpenEpi.com (Dean, Sullivan, 
& Soe, 2011). Chi Square tests were used to determine statistically significant differences 
between groups. Generalized Linear Models (GLM) were used to determine whether 
statistically significant differences existed between the means of programmatic outcomes for 
the SHC Testing Group and the Traditional Testing Group.
RESULTS
SHC Reactivity Rate Determination
For 08/01/2015 through 12/31/2016, there were 3630 SHC tests reported, 442 (12.0%) were 
positive, 3168 (87.0%) were negative, and 20 (1.0%) were inconclusive. Of the 442 positive 
SHC results, 92 (20.8%) had a prior diagnosis of syphilis (even though a screening tool was 
used to minimize SHC testing in this group), 7 (1.6%) had missing information regarding 
prior diagnosis of syphilis or had no further confirmatory testing, leaving 343 (77.6%) who 
had no prior diagnosis of syphilis and had further testing. Of these 343, 158 (46.0%) were 
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considered true positives based on non-treponemal reactive rapid plasma reagin (RPR) and 
treponemal (primarily treponemal enzyme immunoassays [EIA]) testing (157) or a negative 
RPR with a reactive treponemal test and a lesion consistent with primary syphilis (Figure 1). 
Treatment was documented for 157 (99.4%) of the 158 new cases. There were 168 (49.0%) 
false positives that were not reported as new cases and had negative results on the RPR 
(138), treponemal test, or both (29). Finally, 17 (5.0%) of the 343 with reactive SHC were 
considered inconclusive because they were not reported as a new case of syphilis but had 
reactive results on the RPR (7), treponemal test, or had the combination of reactive 
treponemal test /negative RPR (9). The prevalence of new syphilis in the population tested 
(after removing those with inconclusive SHC results, prior syphilis, or no further testing) 
was 4.5% (158/[3630–20-92–7]). Specificity was estimated to be 95% using the false 
positives (168) and all 3168 who tested negative on SHC (3168/[168+3168], x 100). The 
PPV was estimated from the true and false positives to be 48.5% (158/[158+168]) (Table 1).
The largest number of SHCs were done in Orange County, followed by Miami-Dade, 
Escambia, Lee, Alachua, Polk, Duval, Leon, Hillsborough, Palm Beach, and Brevard. These 
counties accounted for approximately 93.0% of all SHC testing conducted and 
approximately 90.0% of all new cases of syphilis that were identified using the SHC test in 
Florida during the time period. The statewide prevalence of newly identified syphilis (those 
cases found using the SHC test) in the populations tested was estimated to be 4.5% (range of 
0.4% to 28.2% in all SHC using counties). Statewide, 48.5% of persons with a positive SHC 
had newly diagnosed syphilis (the positive predictive value). By county, this ranged from 
8.0% to 100%, depending on the prevalence of syphilis among those tested, and was lowest 
in the two highest SHC volume counties. Per county, the specificity ranged from 90.1% to 
100% among the 11 most SHC-using counties (Table 1).
Programmatic Outcomes Assessment Comparing SHC with Traditional Syphilis Testing
The sample size of syphilis cases used in the analyses of programmatic outcomes was 
n=1644 and included those who: (a) were tested for syphilis using SHC or traditional testing 
during the study period, (b) were from the top 11 SHC-using Florida counties, (c) had no 
prior diagnosis of syphilis, and (d) had public initial lab ordering providers. Of these 1644 
cases, 93 were from the SHC testing group and 1551 were from the traditional testing group. 
In the SHC testing group, all 93 cases were treated. In the traditional testing group, 37 of the 
1551 cases (2.4%) were not treated or were otherwise lost to follow-up.
Timeliness of treatment.—Persons tested with SHC were more likely to receive prompt 
treatment than persons from the traditional testing group [same day (RR = 1.88; 95% CI, 
1.54–2.30), 7 days or less (RR = 1.63; 95% CI, 1.44–1.84), 14 days or less (RR = 1.19; 95% 
CI, 1.10–1.28), and 30 days or less (RR = 1.06; 95% CI, 1.03–1.10)]. The average time to 
treatment among those treated was 7.3 days for the SHC group versus 13.0 days for the 
traditional testing group (F=3.55, p=0.06) (Table 2).
Partner Elicitation, Testing, and Treatment.—Among new cases, patients tested with 
the SHC were more likely to name partners than patients who had traditional testing (RR = 
1.44; 95% CI, 1.27–1.63) and they named a higher average number of partners (1.3 
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compared to 0.8 partners) (F=16.79, p<.0001) (Table 2). Patients who had SHC testing were 
more likely to have at least one named partner tested than patients from the traditional 
testing group (RR = 1.45; 95% CI, 1.23–1.72) and they had a higher average number of 
named partners tested (0.9 partners compared to 0.6 partners) (F=20.35, p<.0001) (Table 2). 
The SHC testing group was more likely to have named partners identified as infected than 
was the traditional testing group (RR = 2.34; 95% CI, 1.82–3.01) and had a higher average 
number of named partners identified as infected (0.5 compared to 0.2 partners infected) 
(F=40.20, p<.0001), even when controlling for those who named at least one partner (0.8 
compared to 0.5) (F=19.13, p <.0001) (Table 2). The SHC testing group was more likely to 
have infected partners subsequently treated than was the traditional testing group (RR = 
2.29; 95% CI, 1.77–2.96) and had a higher average number of named infected partners 
treated (0.5 compared to 0.2) (F=37.58, p<.0001) (Table 2).
Survey Interviews of Field Staff
A total of 20 field staff surveys were conducted. These field staff included one test 
administrator and one program manager from each of the high-volume SHC-using programs 
(with one of the test administrators and one of the program managers representing two of the 
high-volume counties that are adjacent to each other). The 20 survey participants reported 
that the training they received from the SHC distributor for using the SHC test prepared 
them to confidently administer the test. Most said the SHC test was easy to use (15/20), test 
results were easy to read (16/20), and that they had confidence in the accuracy of the results 
(12/20). Strengths of the SHC included: (a) highly appropriate to use in outreach settings 
(6/20, 30%), and (b) quick results were appreciated by staff and patients (8/20, 40%). 
Respondents described twenty-two examples in which the SHC test was particularly helpful 
to field staff and/or patients and are elucidated here: (a) confirming syphilis in the presence 
of symptoms (2/20), (b) quickly putting patients’ minds at ease when SHC results were 
negative or making patients aware of the need for further testing when SHC results were 
positive (3/20), (c) testing people who preferred a finger-stick or were afraid of needles 
(16/20), and (d) quickly identifying an infected pregnant patient who was HIV positive 
(1/20).
Settings that survey respondents thought were most appropriate for using the SHC test were 
health department clinics, outreach sites, physician’s offices, emergency rooms, community-
based organizations, jails, STD clinics, and any sites that offer free services. Most 
respondents thought the SHC test was a beneficial addition to traditional syphilis testing 
(16/20). When asked about the percentage of clients who had a difficult time understanding 
what a positive SHC test result meant, the answers varied widely from 0.0% to 80.0%, with 
the majority being 10.0% or less. The respondents further stated that this was “about the 
same” amount as clients who also had difficulty understanding results from traditional 
syphilis testing.
The weaknesses reported for the SHC test were that test kits expired too quickly (2/20) and 
that the pipet included in the test kit was flimsy, making it difficult to get a blood sample 
(7/20). The most common complaint about the SHC test was field staff were concerned there 
may have been too many “false positive” results (14/20).
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Most respondents said they did not notify named partners of clients with positive SHC test 
results until they have the confirmatory test results back (14/20). Replies from the 20 
respondents about beginning treatment for syphilis, based on positive test results from the 
SHC alone, were mixed; five were “highly likely” to begin treatment, five were “likely” to 
begin treatment, one was “neutral,” three were “unlikely,” and six were “very unlikely.” 
Those who were “highly likely” or “likely” to begin treatment reserved this only for clients 
who also had symptoms of syphilis or had a confirmed syphilis exposure.
Most respondents said that positive SHC test results presented no more of a challenge for 
counseling or administering treatment than positive results from traditional syphilis testing 
(17/20). Most respondents also said that the quick results from the SHC test provided a 
better service than traditional testing for clients in settings other than the health clinics 
(17/20). For syphilis testing in settings other than the health clinic (such as outreach sites), 
most respondents said they prefer to use the SHC test because a larger volume of testing can 
be done, and it helps to mitigate the spread of syphilis, especially in jails, where there is a 
readily available audience for testing participation (13/20). Respondents’ opinions varied 
regarding the use of the SHC test in the health clinic settings; five preferred using the SHC 
test alone, four preferred using traditional testing alone, six preferred using both the SHC 
test and traditional testing together, three had no preference, and two were neutral.
DISCUSSION
Using data collected from testing in a wide variety of settings in Florida, we estimate the 
specificity of the SHC was 95.0%, as in many cases the SHC was compared against a non-
treponemal result. Although the specificity was fairly consistent in the 11 different counties 
studied, the proportion of persons with positive tests who were diagnosed as having syphilis 
(predictive value of a positive test) varied, mostly due to differences in the prevalence of 
syphilis among those tested (0.4% to 28.2%). Compared to the traditional testing group, the 
SHC testing group had more timely treatment, more partners named, and more partners 
identified as infected. These enhanced outcomes may be due to quick SHC test results 
allowing for more accurate recall in naming partners, as well as enabling Disease 
Intervention Specialists (DIS) to promptly notify these named partners (Hoots et al., 2014; 
Rudy et al., 2012).
Additionally, a greater sense of urgency for both patient and practitioner may exist when 
SHC results are positive in the presence of signs and symptoms and/or a known syphilis 
exposure. This scenario might create expediency for an intervention conversation at this 
initial encounter to educate the patient and possibly administer treatment. Our findings 
suggest the SHC could improve syphilis control efforts, however the administration and 
selection for SHC testing was not randomly assigned and outcomes were assessed against a 
small sample size of newly detected cases. Going forward, a more rigorous evaluation could 
help determine if the SHC test truly does improve these outcomes.
Our estimated specificity is higher than the specificity estimated in a previous investigation 
in Florida (Matthias et al., 2016). A low specificity could be a serious deterrent to using the 
SHC in low prevalence settings. However, one study concluded that even in low prevalence 
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settings, screening with rapid syphilis testing remains cost-effective and less expensive than 
use of the RPR (Mallma et al., 2016). Before implementing the SHC, program 
administrators should discern the potential value of the test, based on the specific 
characteristics of their individual programs. Given the relatively stable specificity, but highly 
variable PPV, the benefits of the SHC will depend on the population tested.
Field staff liked the SHC test, with a majority citing practicality for use by non-laboratory 
health care workers, flexibility for use in non-traditional settings, and faster test results that 
allowed quicker identification and treatment of new syphilis cases. They also believed that 
use of the SHC test could help reduce the spread of syphilis. Field staff also reported 
concerns about test kits expiring too quickly, challenges in sample collection, and accuracy 
of results. This information helps to fill in previously recognized gaps in understanding of 
the performance, usefulness, and limitations of the SHC (Seña et al., 2010).
This study had several limitations. The sensitivity of the SHC test could not be determined 
because specimens with negative SHC results were not re-tested with other tests to see if any 
infections were missed. The estimated specificity and “false positives” compared results 
from a treponemal-based rapid test to, in many cases, only a non-treponemal test. Although 
these persons would be unlikely to have syphilis, some probably had treponemal antibody 
due to a previous infection. These issues may limit the confidence in the specificity estimate. 
Information from the survey interviews of field staff may be unique to Florida’s syphilis 
prevention program, and therefore may not be generalizable to other programs.
Appendix 1.: Variables of Interest Regarding Programmatic Outcomes
Variable Name Variable Type Definition
SHCa Testing Group Categorical New cases of syphilis identified
with the SHCa test
Traditional Testing Group Categorical New cases of syphilis identified
with traditional syphilis tests
Timeliness of Treatment Categorical and continuous Categorical – mutually inclusive
time interval cut points:
Zero days to treatment
7 days or less to treatment
14 days or less to treatment
30 days or less to treatment
Over 30 days to treatment or no
treatment given
Continuous – time to treatment
in days
Number of Named Partners Categorical and continuous Categorical – stratified
responses as “Yes” (partners
were named) or “No” (zero
partners were named)
Continuous – numbers of
partners named
Number of Named Partners
Who Were Tested
Categorical and continuous Categorical – stratified
responses as “Yes” (named
partners were tested) or “No”
(zero named partners were
tested)
Continuous – numbers of named
partners tested
Number of Named Partners Categorical and continuous Categorical – stratified
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Variable Name Variable Type Definition
Who Were Infected responses as “Yes” (named
partners were infected) or “No”
(zero named partners were
infected)
Continuous – numbers of named
partners infected
Number of Named Partners
Who Were Infected and Treated
Categorical and continuous Categorical – stratified
responses as “Yes” (named
partners were infected and
treated) or “No” (zero named
partners were infected and
treated)
Continuous – numbers of named
partners infected and treated
This table describes the variables of interest used to analyze programmatic outcomes.
aSyphilis Health Check
Appendix 2.: Field Staff Questionnaire – Assessment of the Rapid Syphilis 
Health Check
Name of Staff Member __________________________________________
County Name __________________________________________________
Instructions:
This survey is being done to obtain the perspectives of field staff about syphilis testing using 
the Rapid Syphilis Health Check (RSHC). We would like to know what you think about the 
implementation of syphilis testing using the RSHC in your field setting to help determine 
best practices and effectiveness of this test.
Section A.
Please complete the following questions.
1. What is your primary profession or role? (Check one response only)
□ Nurse □ Phlebotomist
□ Disease Intervention Specialist □ Lab Technician
□ Nurse Practitioner □ Health Support Technician
□ Area Manager □ STD Supervisor
□ Other _________________
2. What is your role in syphilis testing? (Check all that apply)
□ Management or administrative role in syphilis testing
□ Supervise staff conducting syphilis testing
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□ Conduct syphilis testing
□ Provide health care services for patients who have received syphilis testing/screening
□ Teach other providers or students about syphilis testing
□ Follow-up partner services
□ Other (Specify) ___________________________________________________________
Section B.
When answering the following questions, think of the value of the RSHC as a screening test 
for syphilis.
1. Did the training you received for the RSHC test prepare you to confidently administer this 
test to those seeking syphilis testing?
□ Yes        □ No
□ If you answered “no”, please explain:
________________________________________________________________________
________________________________________________________________________
2. Would you rate the RSHC test:
□ Easy to use       □ Difficult to use       □ Neutral
If you answered “difficult”, please explain:
________________________________________________________________________
________________________________________________________________________
3. Did you experience any challenges in administering the RSHC test?
□ Yes        □ No
If you experienced any challenges, please list them here:
________________________________________________________________________
________________________________________________________________________
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Please list any suggestions you may have to address these challenges:
________________________________________________________________________
________________________________________________________________________
4. Would you rate RSHC test results:
□ Easy to read/interpret       □ Difficult to read/interpret       □ Neutral
If you answered “difficult”, please explain:
________________________________________________________________________
________________________________________________________________________
5. Do you have confidence in the accuracy of the RSHC test results?
□ Yes        □ No
Please explain your answer, for either “Yes” or “No”:
________________________________________________________________________
________________________________________________________________________
6. Were there any strengths of the RSHC test as a screening test? If so, please list them:
________________________________________________________________________
________________________________________________________________________
7. Were there any weaknesses of the RSHC test as a screening test? If so, please list them:
________________________________________________________________________
________________________________________________________________________
8. Was there a situation(s) in which you found the RSHC to be particularly helpful?
□ Yes       □ No       □ Unsure/don’t know
Please explain your answer:
________________________________________________________________________
________________________________________________________________________
Richards et al. Page 11
Fla Public Health Rev. Author manuscript; available in PMC 2019 November 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
9. What settings are most appropriate for use of the RSHC test? (Check all that apply)
□ Health Department Clinic       □ Outreach site     □ Physician’s office
□ Emergency Room       □ Community-based Organization
□ Other: ______________________________________________________________
10. Has the use of the RSHC test been a beneficial addition to traditional syphilis testing, or 
would the traditional testing alone suffice?
□ The RSHC has been a beneficial addition
□ The traditional syphilis testing alone would suffice
Please explain your answer:
________________________________________________________________________
________________________________________________________________________
11. In regard to syphilis testing, what is your opinion about patients’ preferences regarding 
having a finger-stick versus having a tube of blood drawn?
□ Patients prefer a finger-stick
□ Patients prefer having a tube of blood drawn
□ Patients have no preference
□ Unsure/don’t know
12. In communicating results of the RSHC test to the patient, what percentage of patients 
would you say had issues in understanding what a positive screening test means?
________________________%
13. Would you say this percentage is higher or lower than traditional syphilis testing?
□ Higher than traditional testing
□ Lower than traditional testing
□ About the same as traditional testing
Section C.
When answering the following questions, think of the value of the RSHC as a tool in your 
arsenal against the spread of syphilis.
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1. As part of the protocol for RSHC testing, a Rapid Syphilis Test Risk Assessment 
questionnaire is completed on all clients to determine whether they are at risk for syphilis. 
Would you say that this questionnaire adequately provides this information?
□ Yes       □ No       □ Neutral       □ Unsure/don’t know
Please explain your answer:
________________________________________________________________________
________________________________________________________________________
2. As part of the protocol for RSHC testing, a Rapid Syphilis Test Risk Assessment 
questionnaire is completed on all clients to determine whether they have a history of 
syphilis. Would you say that this questionnaire adequately provides this information?
□ Yes       □ No       □ Neutral       □ Unsure/don’t know
Please explain your answer:
3. Is the Rapid Syphilis Test Risk Assessment (described in questions 1 and 2 above) 
helpful, as it pertains to the effectiveness in identifying new syphilis cases?
□ Yes       □ No       □ Neutral
Please explain your answer:
________________________________________________________________________
________________________________________________________________________
4. Were partners of patients with positive RSHC test results notified before the patient got 
confirmatory results from traditional syphilis testing?
□ Yes       □ No       □ Unsure/don’t know
If you answered “yes”, did the RSHC test increase the timeliness of partner notification 
versus using traditional syphilis testing alone?
□ Yes       □ No       □ Made no difference       □ Unsure/don’t know
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5. How likely are you to begin treatment for syphilis based on a positive RSHC test result 
(before getting confirmatory test results)? (Check one response only)
□ Highly likely     □ Likely     □ Neutral     □ Unlikely     □ Very unlikely
6. Did positive RSHC test results present more of a challenge to you in how to proceed with 
counseling/administering treatment compared to having a positive result from traditional 
testing?
□ Yes, it presented more of a challenge
□ No, it did not present more of a challenge
□ Neutral, it made no difference either way
Please explain your answer:
________________________________________________________________________
________________________________________________________________________
7. Does the RSHC test, with same day results, (versus traditional syphilis testing, with a 3 – 
7 day wait time for results) better serve the patient population that receives syphilis testing in 
settings other than the health clinic?
□ Yes       □ No       □ Neutral       □ Unsure/don’t know
Please explain your answer:
________________________________________________________________________
________________________________________________________________________
8. For syphilis testing in the health clinic, would you prefer to use the RSHC test or 
traditional syphilis testing alone?
□ RSHC       □ traditional syphilis 
testing alone
      □ No 
preference
      □ Unsure/don’t 
know
Please explain your answer:
________________________________________________________________________
9. For syphilis testing in settings other than the health clinic (such as jail or outreach sites), 
would you prefer to use the RSHC test or traditional syphilis testing alone?
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□ RSHC       □ traditional syphilis 
testing alone
      □ No 
preference
      □ Unsure/don’t 
know
Please explain your answer:
________________________________________________________________________
________________________________________________________________________
Section D.
1. List any benefits or positive outcomes that have resulted from the implementation of the 
RSHC test in your work setting.
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
2. List any problems or negative outcomes that have resulted from the implementation of the 
RSHC test in your work setting.
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
3. Share any other comments about the RSHC test.
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
Thanks for your help!
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Implications for Public Health Practice
The SHC test appears to be an effective screening tool that provides rapid and reliable 
test results, especially in the presence of symptoms, that may facilitate same-day 
treatment or shorter overall time to treatment. The rapid results may enhance timely 
partner notification by reducing delays in new case identification and reporting, as well as 
facilitate successful partner services interactions. In addition, it was highly acceptable to 
both healthcare workers and patients. Our findings about the impact of the SHC on these 
important outcomes are promising. Further research is needed to continue to define the 
benefits and limitations of this new test.
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Figure 1. Flow Chart for Syphilis Health Check Positive Results Leading to New Syphilis Cases
A flow chart showing SHCa positive test results leading to new syphilis cases from 
08/01/2015 through 12/31/2016.
aSyphilis Health Check, bDiagnosis, cRapid Plasma Reagin, dOutlier case conclusively 
identified as primary syphilis
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